Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
KT-253 · 1 trial · 4 indications
Adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0
MTD and RP2D will be determined in patients with R/R high grade myeloid malignancies, ALL, and separately, in patients with lymphomas and advanced solid tumors
| Arm | Type | Description |
|---|---|---|
| Phase 1 Dose Escalation Arm A in patients with R/R Solid Tumors and Lymphomas | EXPERIMENTAL | KT-253 dosed intravenous (IV) once every three weeks in 21-day cycles |
| Phase 1 Dose Escalation Arm B in patients with R/R High Grade Myeloid Malignancies and ALL | EXPERIMENTAL | KT-253 dosed IV once every three weeks in 21-day cycles |
| Name | Type | Description |
|---|---|---|
| KT-253 | DRUG | KT-253 will be administered intravenously per the defined protocol frequency and dose level. |
Inclusion Criteria: 1. All Participants: * Eastern Cooperative Oncology Group performance status: 0-2. * Resolved acute effects of any prior therapy except for alopecia to baseline severity or Grade ≤1 NCI CTCAE and Grade ≤2 neuropathy * Adequate organ function at screening 2. Solid Tumor...
KT-253 is an investigational small molecule being studied for the treatment of myeloid malignancies, including high grade myeloid malignancies. It is also being evaluated in acute lymphocytic leukemia, lymphomas, and advanced solid tumors. The drug is in Phase 1 clinical development and has not been approved by the FDA.
KT-253 is being developed by Kymera Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol KYMR. The company is conducting clinical research on this investigational small molecule for oncology indications.
KT-253 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The drug has received orphan drug designation from the FDA for its intended oncology indications.
KT-253 has one completed Phase 1 clinical trial, identified as NCT05775406. This trial evaluated the safety and clinical activity of KT-253 in adult patients with high grade myeloid malignancies, acute lymphocytic leukemia, lymphoma, and advanced solid tumors. The trial enrolled 52 participants in the United States.
KT-253 is the primary name for this investigational drug developed by Kymera Therapeutics. No alternative names have been reported for this compound in the available clinical trial information.